Antiphospholipid syndrome screening, including anticardiolipin antibodies (aCL); lupus anticoagulant (LA); anti‐beta2‐glycoprotein‐1 (anti‐B2GP1), should be carried out in selected newly diagnosed patients as it may influence choice of subsequent therapy for ITP. The gene discussed is ACLY; the disease is antiphospholipid syndrome.